Severe hepatic and cutaneous adverse effects with nevirapine.
(1) Introduce nevirapine at half the target dose, and monitor the skin, mucous membranes and liver to avoid fatal adverse effects.
D056486:Chemical and Drug Induced Liver Injury; D006801:Humans; D019829:Nevirapine / Q000008:administration & dosage / Q000009:adverse effects*; D010078:Oxazines; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D013262:Stevens-Johnson Syndrome / Q000139:chemically induced / Q000209:etiology
D010078:Oxazines; D018894:Reverse Transcriptase Inhibitors; D019829:Nevirapine